FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965772617> ?p ?o ?g. }

• W1965772617 endingPage "264" @default.
• W1965772617 startingPage "255" @default.
• W1965772617 abstract "Atherosclerosis and its clinical manifestations of heart attack, stroke, and peripheral vascular insufficiency are a major cause of morbidity and mortality among both men and women. Multiple risk factors including hypertension, diabetes mellitus, smoking, and lipoprotein disorders are involved in the pathogenesis of this chronic inflammatory disease of arteries.The development of early atherosclerotic lesions can be subdivided into initiation (formation of small fatty streaks), expansion (vertical and lateral growth and coalescence of fatty streaks), and progression to plaques (intimal smooth muscle cell recruitment, collagen deposition, and formation of a fibrous cap) (reviewed in ref.1). During the initiation and expansion of fatty streaks, circulating monocytes are recruited to the arterial intima where they are transformed into lipid-engorged macrophage foam cells. The arterial endothelium in these regions is activated and expresses inducible leukocyte adhesion molecules and chemokines. Production of cytokines and growth factors within lesions may amplify monocyte recruitment, stimulate macrophage proliferation, and induce migration of smooth muscle cells from the media to the intima of the vessel. Intimal smooth muscle cells deposit collagen and other ECM proteins, leading to the formation of a fibrous cap. Although clinically significant complications of atherosclerosis, such as plaque ulceration, rupture, and thrombosis, occur in established or advanced atherosclerotic plaques, understanding the mechanisms of early lesion formation offers the hope of intervening to delay or prevent lesion progression and complications. A select set of transcription factors may be critical in both the initiation and expansion of lesions, as well as in protecting the vessel wall from the formation of atherosclerotic lesions. In this overview, we will focus on one transcription factor, NF-κB, whose activation has been linked to the onset of atherosclerosis.NF-κB is composed of members of the Rel family that share a 300 amino acid region, known as the Rel homology domain, which mediates dimerization, nuclear translocation, DNA binding, and interaction with NF-κB inhibitors (reviewed in ref.2). Activation of NF-κB is controlled by a family of inhibitors, or IκBs, that bind to NF-κB dimers and mask the nuclear localization sequence of NF-κB, thus retaining the entire complex in the cytoplasm. Diverse stimuli activate NF-κB, through the phosphorylation and activation of the IκB kinase (IKK) complex. This complex consists of IKK-α and IKK-β heterodimers, a number of IKK-γ subunits, and possibly other components that have less certain significance. The activated IKK complex specifically phosphorylates the IκBs, which are then rapidly polyubiquitinated, targeting them for degradation by the proteosome. Following release from the inhibitor, NF-κB dimers translocate from the cytoplasm to the nucleus, where they bind target genes and stimulate transcription (Figure ​(Figure1).1). NF-κB activates a variety of target genes relevant to the pathophysiology of the vessel wall, including cytokines, chemokines, and leukocyte adhesion molecules, as well as genes that regulate cell proliferation and mediate cell survival. NF-κB also activates the IκBα gene, thus replenishing the cytoplasmic pool of its own inhibitor. Restored expression of IκB-α decreases NF-κB activation and diminishes expression of NF-κB–dependent genes. The NF-κB/IκB-α autoregulatory system ensures that the induction of NF-κB is transient and that the activated cell returns to a quiescent state. Physiological modulation and pathological activation of the NF-κB system may contribute to the changes in gene expression that occur during atherogenesis.Figure 1Schematic representation of NF-κB as an integrator in atherogenesis. Many of the diverse agents associated with the onset of lesion formation interact with specific receptors. Angiotensin II (Ang II), cytokines, advanced glycosylation end products ..." @default.
• W1965772617 created "2016-06-24" @default.
• W1965772617 creator A5001212036 @default.
• W1965772617 creator A5058401548 @default.
• W1965772617 date "2001-02-01" @default.
• W1965772617 modified "2023-10-09" @default.
• W1965772617 title "NF-κB: pivotal mediator or innocent bystander in atherogenesis?" @default.
• W1965772617 cites W1480466711 @default.
• W1965772617 cites W1516434930 @default.
• W1965772617 cites W1554317829 @default.
• W1965772617 cites W1557884422 @default.
• W1965772617 cites W1836594018 @default.
• W1965772617 cites W1955583657 @default.
• W1965772617 cites W1976621212 @default.
• W1965772617 cites W1977662482 @default.
• W1965772617 cites W1983398917 @default.
• W1965772617 cites W1985597508 @default.
• W1965772617 cites W1987700050 @default.
• W1965772617 cites W1995900007 @default.
• W1965772617 cites W2020979704 @default.
• W1965772617 cites W2023302566 @default.
• W1965772617 cites W2030592815 @default.
• W1965772617 cites W2038829792 @default.
• W1965772617 cites W2042438285 @default.
• W1965772617 cites W2045869500 @default.
• W1965772617 cites W2046160463 @default.
• W1965772617 cites W2048900216 @default.
• W1965772617 cites W2056034929 @default.
• W1965772617 cites W2074499846 @default.
• W1965772617 cites W2082162145 @default.
• W1965772617 cites W2083217753 @default.
• W1965772617 cites W2087364003 @default.
• W1965772617 cites W2090845578 @default.
• W1965772617 cites W2093410800 @default.
• W1965772617 cites W2098587915 @default.
• W1965772617 cites W2109074735 @default.
• W1965772617 cites W2114704077 @default.
• W1965772617 cites W2115163080 @default.
• W1965772617 cites W2115308311 @default.
• W1965772617 cites W2118986158 @default.
• W1965772617 cites W2128502634 @default.
• W1965772617 cites W2129313145 @default.
• W1965772617 cites W2130289842 @default.
• W1965772617 cites W2131222777 @default.
• W1965772617 cites W2133694559 @default.
• W1965772617 cites W2136516946 @default.
• W1965772617 cites W2138758296 @default.
• W1965772617 cites W2159742257 @default.
• W1965772617 cites W2166469889 @default.
• W1965772617 cites W2295402402 @default.
• W1965772617 cites W2310033666 @default.
• W1965772617 cites W2313837936 @default.
• W1965772617 cites W2323783182 @default.
• W1965772617 cites W2324841714 @default.
• W1965772617 cites W2430175701 @default.
• W1965772617 cites W2739174192 @default.
• W1965772617 cites W4319308505 @default.
• W1965772617 doi "https://doi.org/10.1172/jci10373" @default.
• W1965772617 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/199202" @default.
• W1965772617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11160146" @default.
• W1965772617 hasPublicationYear "2001" @default.
• W1965772617 type Work @default.
• W1965772617 sameAs 1965772617 @default.
• W1965772617 citedByCount "685" @default.
• W1965772617 countsByYear W19657726172012 @default.
• W1965772617 countsByYear W19657726172013 @default.
• W1965772617 countsByYear W19657726172014 @default.
• W1965772617 countsByYear W19657726172015 @default.
• W1965772617 countsByYear W19657726172016 @default.
• W1965772617 countsByYear W19657726172017 @default.
• W1965772617 countsByYear W19657726172018 @default.
• W1965772617 countsByYear W19657726172019 @default.
• W1965772617 countsByYear W19657726172020 @default.
• W1965772617 countsByYear W19657726172021 @default.
• W1965772617 countsByYear W19657726172022 @default.
• W1965772617 countsByYear W19657726172023 @default.
• W1965772617 crossrefType "journal-article" @default.
• W1965772617 hasAuthorship W1965772617A5001212036 @default.
• W1965772617 hasAuthorship W1965772617A5058401548 @default.
• W1965772617 hasBestOaLocation W19657726171 @default.
• W1965772617 hasConcept C104317684 @default.
• W1965772617 hasConcept C123298856 @default.
• W1965772617 hasConcept C19106626 @default.
• W1965772617 hasConcept C203014093 @default.
• W1965772617 hasConcept C2107291 @default.
• W1965772617 hasConcept C2776914184 @default.
• W1965772617 hasConcept C2777730290 @default.
• W1965772617 hasConcept C502942594 @default.
• W1965772617 hasConcept C54355233 @default.
• W1965772617 hasConcept C71924100 @default.
• W1965772617 hasConcept C86339819 @default.
• W1965772617 hasConcept C86803240 @default.
• W1965772617 hasConcept C95444343 @default.
• W1965772617 hasConceptScore W1965772617C104317684 @default.
• W1965772617 hasConceptScore W1965772617C123298856 @default.
• W1965772617 hasConceptScore W1965772617C19106626 @default.
• W1965772617 hasConceptScore W1965772617C203014093 @default.
• W1965772617 hasConceptScore W1965772617C2107291 @default.

• next